

# Contents

## 1 An Introduction to Primary Immunodeficiency Diseases ..... 1

Nima Rezaei, Francisco A. Bonilla,  
Kathleen E. Sullivan, Esther de Vries,  
and Jordan S. Orange

1.1	Definition	1
1.1.1	Background	1
1.1.2	History	2
1.1.3	Registries	2
1.2	Etiology	2
1.2.1	Classification	2
1.2.2	Genetic Defects	11
1.2.3	Pathophysiology	12
1.3	Clinical Manifestations	14
1.3.1	Infections	14
1.3.2	Autoimmunity	15
1.3.3	Malignancies	19
1.3.4	Other Manifestations	19
1.4	Diagnosis	20
1.4.1	Warning Signs and Symptoms	20
1.4.2	Diagnostic Approach	21
1.4.3	Laboratory Tests	24
1.5	Management	25
1.5.1	General Considerations	25
1.5.2	Vaccination	26
1.5.3	Antibiotics	27
1.5.4	Immunoglobulin Replacement Therapy	28
1.5.5	Transplantation	28
1.5.6	Gene Therapy	29
1.5.7	Adjunct Therapies	29

## 2 Combined T and B Cell Immunodeficiencies ..... 39

Françoise Le Deist, Despina Moshous, Steven J. Howe,  
Amit Nahum, Fotini D. Kavadas, Elana Lavine,  
Chaim M. Roifman, and Alain Fischer

2.1	Introduction	39
-----	--------------	----

2.2	T-B+ Severe Combined Immunodeficiency ( $\gamma$ c Deficiency, JAK3 Deficiency, IL7-R $\gamma$ Deficiency, CD45 Deficiency, CD3 $\gamma$ / CD3 $\lambda$ /CD3 $\epsilon$ /CD3 $\xi$ Deficiencies)	42
2.2.1	Definition	42
2.2.2	Etiology	42
2.2.3	Clinical Manifestations	44
2.2.4	Diagnosis	45
2.2.5	Management	46
2.3	T-B- Severe Combined Immunodeficiency (RAG1/2 Deficiencies, Artemis Deficiency, ADA Deficiency)	48
2.3.1	Definition	48
2.3.2	Etiology	49
2.3.3	Clinical Manifestations	52
2.3.4	Diagnosis	52
2.3.5	Management	52
2.4	Omenn Syndrome	53
2.4.1	Definition	53
2.4.2	Etiology	53
2.4.3	Clinical Manifestations	53
2.4.4	Diagnosis	53
2.4.5	Management	54
2.5	DNA Ligase IV Deficiency	54
2.5.1	Definition	54
2.5.2	Etiology	54
2.5.3	Clinical Manifestations	54
2.5.4	Diagnosis	55
2.5.5	Management	55
2.6	Cernunnos Deficiency	55
2.6.1	Definition	55
2.6.2	Etiology	55
2.6.3	Clinical Manifestations	55
2.6.4	Diagnosis	55
2.6.5	Management	56
2.7	Purine Nucleoside Phosphorylase (PNP) Deficiency	56
2.7.1	Definition	56
2.7.2	Etiology	56
2.7.3	Clinical Manifestations	57

2.7.4	Diagnosis	58	2.14.4	Diagnosis	73
2.7.5	Management	58	2.14.5	Management	74
2.8	Immunoglobulin Class Switch Recombination Deficiencies (affecting CD40–CD40L) ( <i>CD40 ligand</i> <i>Deficiency, CD40 Deficiency</i> )	59	2.15	CD25 Deficiency	74
2.8.1	Definition	59	2.15.1	Definition	74
2.8.2	Etiology	59	2.15.2	Etiology	74
2.8.3	Clinical Manifestations	60	2.15.3	Clinical Manifestations	75
2.8.4	Diagnosis	61	2.15.4	Diagnosis	75
2.8.5	Management	61	2.15.5	Management	76
2.9	MHC Class II Deficiency ( <i>CIITA</i> <i>Deficiency, RFX5 Deficiency, RFXAP</i> <i>Deficiency, RFXANK Deficiency</i> )	62	2.16	STAT5B Deficiency	76
2.9.1	Definition	62	2.16.1	Definition	76
2.9.2	Etiology	62	2.16.2	Etiology	76
2.9.3	Clinical Manifestations	63	2.16.3	Clinical Manifestations	77
2.9.4	Diagnosis	64	2.16.4	Diagnosis	77
2.9.5	Management	64	2.16.5	Management	78
2.10	MHC Class I Deficiency ( <i>TAP1/2</i> <i>Deficiencies, Tapasin Deficiency</i> )	65	<b>3</b>	<b>Predominantly Antibody Deficiencies</b>	<b>97</b>
2.10.1	Definition	65		Asghar Aghamohammadi, Vassilios Lougaris, Alessandro Plebani, Toshio Miyawaki, Anne Durandy, and Lennart Hammarström	
2.10.2	Etiology	65	3.1	Introduction	97
2.10.3	Clinical Manifestations	66	3.2	Agammaglobulinemia with Absent B Cells ( <i>Btk Deficiency, <math>\mu</math> Heavy Chain</i> <i>Deficiency, <math>\lambda</math>5/14.1 Deficiency,</i> <i>Ig<math>\alpha</math> Deficiency, Ig<math>\beta</math> Deficiency, BLNK</i> <i>Deficiency, LRRC8 Deficiency, Other</i> <i>Forms of Agammaglobulinemia</i> )	99
2.10.4	Diagnosis	67	3.2.1	Definition	99
2.10.5	Management	67	3.2.2	Etiology	99
2.11	CD8 Deficiency ( <i>CD8<math>\alpha</math> Chain Defect,</i> <i>ZAP-70 Deficiency</i> )	68	3.2.3	Clinical Manifestations	101
2.11.1	Definition	68	3.2.4	Diagnosis	104
2.11.2	Etiology	68	3.2.5	Management	104
2.11.3	Clinical Manifestations	69	3.3	Hypogammaglobulinemia with Normal/Low Number of B Cells ( <i>Common Variable</i> <i>Immunodeficiency, ICOS Deficiency,</i> <i>TACI Deficiency, CD19 Deficiency,</i> <i>Other Forms of</i> <i>Hypogammaglobulinemia</i> )	105
2.11.4	Diagnosis	69	3.3.1	Definition	105
2.11.5	Management	70	3.3.2	Etiology	105
2.12	CD4 Deficiency ( <i>p56lck Deficiency,</i> <i>Idiopathic CD4 Lymphopenia</i> )	70	3.3.3	Clinical Manifestations	108
2.12.1	Definition	70	3.3.4	Diagnosis	110
2.12.2	Etiology	70	3.3.5	Management	110
2.12.3	Clinical Manifestations	71	3.4	Immunoglobulin Class Switch Recombination Deficiencies (Due to Intrinsic B Cell Defects) ( <i>AID Deficiency, UNG Deficiency,</i> <i>Other CSR Selective Deficiencies</i> )	111
2.12.4	Diagnosis	71	3.4.1	Definition	111
2.12.5	Management	71	3.4.2	Etiology	111
2.13	CRAC Deficiency	72			
2.13.1	Definition	72			
2.13.2	Etiology	72			
2.13.3	Clinical Manifestations	72			
2.13.4	Diagnosis	72			
2.13.5	Management	73			
2.14	Winged-Helix-Nude (WHN) Deficiency	73			
2.14.1	Definition	73			
2.14.2	Etiology	73			
2.14.3	Clinical Manifestations	73			

3.4.3	Clinical Manifestations . . . . .	113	4.3	Cyclic Neutropenia . . . . .	135
3.4.4	Diagnosis . . . . .	113	4.3.1	Definition . . . . .	135
3.4.5	Management . . . . .	113	4.3.2	Etiology . . . . .	135
3.5	Selective IgA Deficiency . . . . .	113	4.3.3	Clinical Manifestations . . . . .	136
3.5.1	Definition . . . . .	113	4.3.4	Diagnosis . . . . .	136
3.5.2	Etiology . . . . .	114	4.3.5	Management . . . . .	136
3.5.3	Clinical Manifestations . . . . .	114	4.4	Leukocyte Adhesion Deficiency (LAD Types 1–3) . . . . .	136
3.5.4	Diagnosis . . . . .	115	4.4.1	Definition . . . . .	136
3.5.5	Management . . . . .	115	4.4.2	Etiology . . . . .	137
3.6	Other Immunoglobulin Isotypes or Light Chain Deficiencies ( <i>Isolated IgG Subclass Deficiency, IgA with IgG Subclass Deficiency, Ig Heavy Chain Deletions, κ Light Chain Deficiency</i> ) . . . . .	116	4.4.3	Clinical Manifestations . . . . .	137
3.6.1	Definition . . . . .	116	4.4.4	Diagnosis . . . . .	139
3.6.2	Etiology . . . . .	116	4.4.5	Management . . . . .	139
3.6.3	Clinical Manifestations . . . . .	116	4.5	RAC-2 Deficiency . . . . .	141
3.6.4	Diagnosis . . . . .	117	4.5.1	Definition . . . . .	141
3.6.5	Management . . . . .	117	4.5.2	Etiology . . . . .	141
3.7	Specific Antibody Deficiency with Normal Immunoglobulin Concentrations . . . . .	117	4.5.3	Clinical Manifestations . . . . .	141
3.7.1	Definition . . . . .	117	4.5.4	Diagnosis . . . . .	141
3.7.2	Etiology . . . . .	117	4.5.5	Management . . . . .	141
3.7.3	Clinical Manifestations . . . . .	118	4.6	β-Actin Deficiency . . . . .	141
3.7.4	Diagnosis . . . . .	118	4.6.1	Definition . . . . .	141
3.7.5	Management . . . . .	118	4.6.2	Etiology . . . . .	141
3.8	Transient Hypogammaglobulinemia of Infancy . . . . .	118	4.6.3	Clinical Manifestations . . . . .	142
3.8.1	Definition . . . . .	118	4.6.4	Diagnosis . . . . .	143
3.8.2	Etiology . . . . .	118	4.6.5	Management . . . . .	143
3.8.3	Clinical Manifestations . . . . .	118	4.7	Chronic Granulomatous Disease (CGD) ( <i>gp91<sup>phox</sup> Deficiency, p22<sup>phox</sup> Deficiency, p47<sup>phox</sup> Deficiency, p67<sup>phox</sup> Deficiency</i> ) . . . . .	143
3.8.4	Diagnosis . . . . .	119	4.7.1	Definition . . . . .	143
3.8.5	Management . . . . .	119	4.7.2	Etiology . . . . .	143
<b>4</b>	<b>Phagocytes Defects . . . . .</b>	<b>131</b>	4.7.3	Clinical Manifestations . . . . .	144
	Uwe Wintergerst, Sergio D. Rosenzweig, Mario Abinun, Harry L. Malech, Steven M. Holland, and Nima Rezaei		4.7.4	Diagnosis . . . . .	148
4.1	Introduction . . . . .	131	4.7.5	Management . . . . .	149
4.2	Severe Congenital Neutropenias ( <i>ELA2 Deficiency, GFI1 Deficiency, HAX1 Deficiency, CSF3R Deficiency, Neutropenia with Myelodysplasia</i> ) . . . . .	131	4.8	Neutrophil G-6PD Deficiency . . . . .	152
4.2.1	Definition . . . . .	131	4.8.1	Definition . . . . .	152
4.2.2	Etiology . . . . .	132	4.8.2	Etiology . . . . .	153
4.2.3	Clinical Manifestations . . . . .	134	4.8.3	Clinical Manifestations . . . . .	153
4.2.4	Diagnosis . . . . .	134	4.8.4	Diagnosis . . . . .	153
4.2.5	Management . . . . .	134	4.8.5	Management . . . . .	153
			4.9	Myeloperoxidase Deficiency . . . . .	153
			4.9.1	Definition . . . . .	153
			4.9.2	Etiology . . . . .	153
			4.9.3	Clinical Manifestations . . . . .	153
			4.9.4	Diagnosis . . . . .	154
			4.9.5	Management . . . . .	154
			4.10	Specific Granule Deficiency . . . . .	154
			4.10.1	Definition . . . . .	154
			4.10.2	Etiology . . . . .	154

4.10.3	Clinical Manifestations . . . . .	154	5.4.4	Diagnosis . . . . .	177
4.10.4	Diagnosis . . . . .	154	5.4.5	Management . . . . .	178
4.10.5	Management . . . . .	155	5.5	Autoimmune Lymphoproliferative Syndrome (ALPS) ( <i>ALPS Ia, Ib, IIa,</i> <i>IIf, III</i> ) . . . . .	178
4.11	Shwachman–Diamond Syndrome . . . . .	155	5.5.1	Definition . . . . .	178
4.11.1	Definition . . . . .	155	5.5.2	Etiology . . . . .	178
4.11.2	Etiology . . . . .	155	5.5.3	Clinical Manifestations . . . . .	180
4.11.3	Clinical Manifestations . . . . .	156	5.5.4	Diagnosis . . . . .	180
4.11.4	Diagnosis . . . . .	156	5.5.5	Management . . . . .	181
4.11.5	Management . . . . .	157	5.6	Autoimmune Polyendocrinopathy with Candidiasis and Ectodermal Dystrophy (APECED) . . . . .	182
4.12	Localised Juvenile Periodontitis . . . . .	158	5.6.1	Definition . . . . .	182
4.12.1	Definition . . . . .	158	5.6.2	Etiology . . . . .	182
4.12.2	Etiology . . . . .	158	5.6.3	Clinical Manifestations . . . . .	182
4.12.3	Clinical Manifestations . . . . .	158	5.6.4	Diagnosis . . . . .	183
4.12.4	Diagnosis . . . . .	158	5.6.5	Management . . . . .	184
4.12.5	Management . . . . .	158	5.7	Immunodysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) . . . . .	184
4.13	Papillon–Lefèvre Syndrome . . . . .	158	5.7.1	Definition . . . . .	184
4.13.1	Definition . . . . .	158	5.7.2	Etiology . . . . .	184
4.13.2	Etiology . . . . .	158	5.7.3	Clinical Manifestations . . . . .	185
4.13.3	Clinical Manifestations . . . . .	159	5.7.4	Diagnosis . . . . .	186
4.13.4	Diagnosis . . . . .	159	5.7.5	Management . . . . .	186
4.13.5	Management . . . . .	159			
<b>5</b>	<b>Genetic Disorders of Immune Regulation . . . . .</b>	<b>167</b>	<b>6</b>	<b>Defects in Innate Immunity: Receptors and Signaling Components . . . . .</b>	<b>195</b>
	Carsten Speckmann, Jan Rohr, and Stephan Ehl			Nima Parvaneh, Joachim Roesler, Steven M. Holland, and Tim Niehues	
5.1	Introduction . . . . .	167	6.1	Introduction . . . . .	195
5.2	Familial Hemophagocytic Lymphohistiocytosis ( <i>Perforin Deficiency,</i> <i>MUNC13-4 Deficiency, Syntaxin 11</i> <i>Deficiency</i> ) . . . . .	168	6.2	Defective Toll-Like Receptor (TLR) Signaling Without Ectodermal Dysplasia ( <i>IRAK-4</i> <i>Deficiency, TLR3 Deficiency,</i> <i>UNC-93B Deficiency</i> ) . . . . .	196
5.2.1	Definition . . . . .	168	6.2.1	Definition . . . . .	196
5.2.2	Etiology . . . . .	168	6.2.2	Etiology . . . . .	198
5.2.3	Clinical Manifestations . . . . .	169	6.2.3	Clinical Manifestations . . . . .	198
5.2.4	Diagnosis . . . . .	169	6.2.4	Diagnosis . . . . .	198
5.2.5	Management . . . . .	171	6.2.5	Management . . . . .	199
5.3	Immunodeficiency with Hypopigmentation ( <i>Chediak-Higashi Syndrome, Griscelli</i> <i>Syndrome, Type II, Hermansky-Pudlak</i> <i>Syndrome, Type II, p14 Deficiency</i> ) . . . . .	172	6.3	Defective Toll-Like Receptor (TLR) Signaling with Ectodermal Dysplasia ( <i>XL- and AD-Anhidrotic Ectodermal</i> <i>Dysplasias with Immunodeficiency</i> ) . . . . .	199
5.3.1	Definition . . . . .	172	6.3.1	Definition . . . . .	199
5.3.2	Etiology . . . . .	172	6.3.2	Etiology . . . . .	199
5.3.3	Clinical Manifestations . . . . .	173	6.3.3	Clinical Manifestations . . . . .	200
5.3.4	Diagnosis . . . . .	173	6.3.4	Diagnosis . . . . .	201
5.3.5	Management . . . . .	174	6.3.5	Management . . . . .	201
5.4	X-Linked Lymphoproliferative Syndrome (XLP) ( <i>SAP Deficiency,</i> <i>XIAP Deficiency</i> ) . . . . .	175			
5.4.1	Definition . . . . .	175			
5.4.2	Etiology . . . . .	175			
5.4.3	Clinical Manifestations . . . . .	176			

6.4	Mendelian Susceptibility to Mycobacterial Diseases ( <i>IFN-<math>\gamma</math> Receptor 1/2 Deficiencies, IL-12/23 Receptor <math>\beta</math>1 Chain Deficiency, IL-12p40 Deficiency, STAT1 Deficiency, LZ-NEMO Deficiency</i> ) . . . . .	201
6.4.1	Definition . . . . .	201
6.4.2	Etiology . . . . .	202
6.4.3	Clinical Manifestations . . . . .	203
6.4.4	Diagnosis . . . . .	203
6.4.5	Management . . . . .	204
6.5	Warts, Hypogammaglobulinemia, Infections, Myelokathexis (WHIM) Syndrome . . . . .	205
6.5.1	Definition . . . . .	205
6.5.2	Etiology . . . . .	205
6.5.3	Clinical Manifestations . . . . .	205
6.5.4	Diagnosis . . . . .	206
6.5.5	Management . . . . .	206
6.6	Epidermodysplasia Verruciformis ( <i>EV Types 1,2</i> ) . . . . .	207
6.6.1	Definition . . . . .	207
6.6.2	Etiology . . . . .	207
6.6.3	Clinical Manifestations . . . . .	207
6.6.4	Diagnosis . . . . .	208
6.6.5	Management . . . . .	208
<b>7</b>	<b>Autoinflammatory Disorders . . . . .</b>	<b>215</b>
	Stefan Berg and Anders Fasth	
7.1	Introduction . . . . .	215
7.2	Familial Mediterranean Fever (FMF) . . . . .	217
7.2.1	Definition . . . . .	217
7.2.2	Etiology . . . . .	218
7.2.3	Clinical Manifestations . . . . .	218
7.2.4	Diagnosis . . . . .	219
7.2.5	Management . . . . .	219
7.3	Mevalonate Kinase Deficiency (MKD) ( <i>Hyperimmunoglobulinemia D and Periodic Fever Syndrome, Mevalonic aciduria</i> ) . . . . .	220
7.3.1	Definition . . . . .	220
7.3.2	Etiology . . . . .	220
7.3.3	Clinical Manifestations . . . . .	220
7.3.4	Diagnosis . . . . .	221
7.3.5	Management . . . . .	221
7.4	Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) . . . . .	221
7.4.1	Definition . . . . .	221
7.4.2	Etiology . . . . .	222
7.4.3	Clinical Manifestations . . . . .	222
7.4.4	Diagnosis . . . . .	222
7.4.5	Management . . . . .	223
7.5	Cryopyrin-Associated Periodic Syndrome (CAPS) ( <i>Chronic Infantile Neurological Cutaneous Articular Syndrome, Muckle–Wells Syndrome, Familial Cold Autoinflammatory Syndrome</i> ) . . . . .	223
7.5.1	Definition . . . . .	223
7.5.2	Etiology . . . . .	223
7.5.3	Clinical Manifestations . . . . .	223
7.5.4	Diagnosis . . . . .	224
7.5.5	Management . . . . .	224
7.6	Blau Syndrome . . . . .	224
7.6.1	Definition . . . . .	224
7.6.2	Etiology . . . . .	224
7.6.3	Clinical Manifestations . . . . .	225
7.6.4	Diagnosis . . . . .	225
7.6.5	Management . . . . .	225
7.7	Pyogenic Arthritis, Pyoderma Gangrenosum and Acne Syndrome (PAPA) . . . . .	225
7.7.1	Definition . . . . .	225
7.7.2	Etiology . . . . .	225
7.7.3	Clinical Manifestations . . . . .	225
7.7.4	Diagnosis . . . . .	226
7.7.5	Management . . . . .	226
7.8	Multifactorial/Polygenic Autoinflammatory Diseases . . . . .	226
7.8.1	Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) . . . . .	226
7.8.2	Systemic Onset Juvenile Idiopathic Arthritis (SoJIA) . . . . .	227
7.8.3	Adult-Onset Still’s Disease (AOSD) . . . . .	227
7.8.4	Chronic Recurrent Multifocal Osteomyelitis (CRMO) . . . . .	227
7.8.5	Crohn’s Disease (CD) . . . . .	227
7.8.6	Behçet’s Disease (BD) . . . . .	227
7.8.7	“Undifferentiated” . . . . .	228
<b>8</b>	<b>Complement Deficiencies . . . . .</b>	<b>235</b>
	Maryam Mahmoudi, Tom Eirik Mollnes, Taco W. Kuijpers, and Dirk Roos	
8.1	Introduction . . . . .	235
8.2	Deficiencies of Classical Pathway Components ( <i>C1q/C1r/C1s Deficiencies, C4 Deficiency, C2 Deficiency</i> ) . . . . .	238
8.2.1	Definition . . . . .	238

8.2.2	Etiology . . . . .	238	9.2	Other Syndromes Associated with Defective DNA Repair ( <i>Ataxia- Telangiectasia, Ataxia-Like Syndrome, Nijmegen Breakage Syndrome, Bloom's Syndrome, ICF Syndrome</i> ) . . . . .	252
8.2.3	Clinical Manifestations . . . . .	239	9.2.1	Definition . . . . .	252
8.2.4	Diagnosis . . . . .	239	9.2.2	Etiology . . . . .	253
8.2.5	Management . . . . .	239	9.2.3	Clinical Manifestations . . . . .	254
8.3	Deficiencies of Lectin Pathway Components ( <i>MBL Deficiency, MASP2 Deficiency</i> ) . . . . .	239	9.2.4	Diagnosis . . . . .	257
8.3.1	Definition . . . . .	239	9.2.5	Management . . . . .	257
8.3.2	Etiology . . . . .	240	9.3	Di George Syndrome . . . . .	258
8.3.3	Clinical Manifestations . . . . .	240	9.3.1	Definition . . . . .	258
8.3.4	Diagnosis . . . . .	240	9.3.2	Etiology . . . . .	258
8.3.5	Management . . . . .	240	9.3.3	Clinical Manifestations . . . . .	259
8.4	Deficiencies of Alternative Pathway Components ( <i>Factor D Deficiency, Properdin Deficiency</i> ) . . . . .	240	9.3.4	Diagnosis . . . . .	261
8.4.1	Definition . . . . .	240	9.3.5	Management . . . . .	261
8.4.2	Etiology . . . . .	241	9.4	Wiskott-Aldrich Syndrome . . . . .	262
8.4.3	Clinical Manifestations . . . . .	241	9.4.1	Definition . . . . .	262
8.4.4	Diagnosis . . . . .	241	9.4.2	Etiology . . . . .	262
8.4.5	Management . . . . .	241	9.4.3	Clinical Manifestations . . . . .	264
8.5	Deficiency of Complement Component C3 . . . . .	241	9.4.4	Diagnosis . . . . .	265
8.5.1	Definition . . . . .	241	9.4.5	Management . . . . .	266
8.5.2	Etiology . . . . .	242	9.5	Hyper-IgE Syndrome ( <i>Stat3 Deficiency, Tyk2 Deficiency, HIES with Unknown Origin</i> ) . . . . .	267
8.5.3	Clinical Manifestations . . . . .	242	9.5.1	Definition . . . . .	267
8.5.4	Diagnosis . . . . .	242	9.5.2	Etiology . . . . .	267
8.5.5	Management . . . . .	242	9.5.3	Clinical Manifestations . . . . .	267
8.6	Deficiencies of Terminal Pathway Components ( <i>C5-9 Deficiencies</i> ) . . . . .	242	9.5.4	Diagnosis . . . . .	268
8.6.1	Definition . . . . .	242	9.5.5	Management . . . . .	269
8.6.2	Etiology . . . . .	242	9.6	Immuno-Osseous Dysplasias ( <i>Schimke Syndrome, Cartilage Hair Hypoplasia</i> ) . . . . .	269
8.6.3	Clinical Manifestations . . . . .	242	9.6.1	Definition . . . . .	269
8.6.4	Diagnosis . . . . .	242	9.6.2	Etiology . . . . .	270
8.6.5	Management . . . . .	243	9.6.3	Clinical Manifestations . . . . .	271
8.7	Deficiencies of Complement Regulatory Proteins ( <i>C1 Inhibitor Deficiency, Factor I Deficiency, Factor H Deficiency, CD46 Deficiency, CD55 Deficiency, CD59 Deficiency</i> ) . . . . .	243	9.6.4	Diagnosis . . . . .	272
8.7.1	Definition . . . . .	243	9.6.5	Management . . . . .	272
8.7.2	Etiology . . . . .	243	9.7	Chronic Mucocutaneous Candidiasis . . . . .	272
8.7.3	Clinical Manifestations . . . . .	244	9.7.1	Definition . . . . .	272
8.7.4	Diagnosis . . . . .	245	9.7.2	Etiology . . . . .	273
8.7.5	Management . . . . .	246	9.7.3	Clinical Manifestations . . . . .	273
9	<b>Other Well-Defined Immunodeficiencies . . . . .</b>	<b>251</b>	9.7.4	Diagnosis . . . . .	274
	Mehdi Yeganeh, Eleonora Gambineri, Kamran Abolmaali, Banafshe Tamizifar, and Teresa Español		9.7.5	Management . . . . .	274
9.1	Introduction . . . . .	251	9.8	Netherton Syndrome . . . . .	274
			9.8.1	Definition . . . . .	274
			9.8.2	Etiology . . . . .	275
			9.8.3	Clinical Manifestations . . . . .	275
			9.8.4	Diagnosis . . . . .	276
			9.8.5	Management . . . . .	276
			9.9	Dyskeratosis Congenita and Høyeraal- Hreidarsson Syndrome . . . . .	276

9.9.1	Definition . . . . .	276	10.4.10	OLEDAID Syndrome . . . . .	299
9.9.2	Etiology . . . . .	276	10.4.11	Dyskeratosis Congenita . . . . .	300
9.9.3	Clinical Manifestations . . . . .	277	10.4.12	Hermansky–Pudlak Syndrome, Type II . . . . .	300
9.9.4	Diagnosis . . . . .	278	10.4.13	Poikiloderma with Neutropenia . . . . .	300
9.9.5	Management . . . . .	278	10.4.14	Acrodermatitis Enteropathica . . . . .	300
<b>10 Syndromic Immunodeficiencies . . . . . 291</b>			10.4.15	Netherton Syndrome . . . . .	300
Jeffrey E. Ming and E. Richard Stiehm			10.4.16	p14 Deficiency . . . . .	300
10.1	Introduction . . . . .	291	10.5	Syndromes Associated with Neurologic Dysfunction . . . . .	300
10.2	Syndromes Associated with Growth Deficiency . . . . .	293	10.5.1	Myotonic Dystrophy . . . . .	300
10.2.1	Cartilage Hair Hypoplasia . . . . .	294	10.5.2	Høyeraal–Hreidarsson Syndrome . . . . .	301
10.2.2	Schimke Immuno-osseous Dysplasia . . . . .	294	10.5.3	Cohen Syndrome . . . . .	301
10.2.3	Short-Limb Skeletal Dysplasia with Combined Immunodeficiency . . . . .	294	10.6	Inborn Errors of Metabolism Associated with Immunodeficiency . . . . .	301
10.2.4	Roifman Syndrome (Roifman Syndrome 1) . . . . .	294	10.6.1	Adenosine Deaminase Deficiency . . . . .	301
10.2.5	Roifman–Costa Syndrome (Roifman Syndrome 2) . . . . .	294	10.6.2	Purine Nucleoside Phosphorylase Deficiency . . . . .	301
10.2.6	Spondyloenchondrodysplasia	295	10.6.3	Leukocyte Adhesion Deficiency, Type 2 . . . . .	301
10.2.7	Growth Hormone Pathway Defects . . . . .	295	10.6.4	Congenital Disorders of Glycosylation, Type I . . . . .	302
10.2.8	Kabuki Syndrome . . . . .	295	10.6.5	Glycogen Storage Disease Ib/Ic . . . . .	303
10.2.9	CHARGE Association . . . . .	295	10.6.6	Barth Syndrome . . . . .	303
10.2.10	Rubinstein–Taybi Syndrome . . . . .	295	10.6.7	Galactosemia . . . . .	303
10.2.11	Mulvihill–Smith Syndrome . . . . .	296	10.6.8	Branched-Chain Amino Acidurias . . . . .	303
10.3	Syndromes Associated with Gastrointestinal Dysfunction . . . . .	296	10.6.9	Lysinuric Protein Intolerance . . . . .	303
10.3.1	Shwachman–Diamond Syndrome . . . . .	298	10.7	Syndromes with Chromosome Instability and/or Defective DNA Repair Associated with Immunodeficiency . . . . .	303
10.3.2	Familial Intestinal Polyatresia . . . . .	298	10.7.1	Nijmegen Breakage Syndrome . . . . .	303
10.3.3	Trichohepatoenteric Syndrome . . . . .	298	10.7.2	Bloom Syndrome . . . . .	304
10.4	Syndromes Associated with Cutaneous Abnormalities . . . . .	298	10.7.3	Ataxia–Telangiectasia . . . . .	304
10.4.1	Wiskott–Aldrich Syndrome . . . . .	298	10.7.4	DNA Ligase IV Deficiency . . . . .	305
10.4.2	Chediak–Higashi Syndrome . . . . .	298	10.7.5	ICF Syndrome . . . . .	305
10.4.3	Griscelli Syndrome, Type II . . . . .	298	10.7.6	Fanconi Pancytopenia . . . . .	305
10.4.4	Omenn Syndrome . . . . .	298	10.8	Syndromes Associated with Chromosomal Abnormalities of Number or Structure . . . . .	305
10.4.5	WHN Deficiency . . . . .	299	10.8.1	Deletions of 22q11 and 10p13–p14 . . . . .	305
10.4.6	Papillon–Lefèvre Syndrome . . . . .	299	10.8.2	Trisomy 21 . . . . .	305
10.4.7	WHIM Syndrome . . . . .	299			
10.4.8	Hypohidrotic/Anhidrotic Ectodermal Dysplasia . . . . .	299			
10.4.9	Incontinentia Pigmenti . . . . .	299			

10.8.3	Partial Deletions of Chromosome 4p. . . . .	306
10.8.4	Turner Syndrome . . . . .	306
<b>11</b>	<b>Treatment of Primary Immunodeficiency Diseases . . . . .</b>	<b>315</b>
	Hale Yarmohammadi and Charlotte Cunningham-Rundles	
11.1	Introduction . . . . .	315
11.2	Therapy for Combined T and B Cell Immunodeficiencies . . . . .	315
11.2.1	Severe Combined Immunodeficiency . . . . .	315
11.2.2	Immunoglobulin Class Switch Recombination Deficiencies (Affecting CD40-CD40L) . . . . .	317
11.2.3	MHC Class II Deficiency . . . . .	318
11.3	Therapy for Predominantly Antibody Deficiencies . . . . .	318
11.3.1	Agammaglobulinemia with Absent B Cells . . . . .	318
11.3.2	Hypogammaglobulinemia with Normal/Low Number of B Cells . . . . .	319
11.3.3	Immunoglobulin Class Switch Recombination Deficiencies (Due to Intrinsic B Cell Defects) . . . . .	319
11.3.4	Selective IgA Deficiency . . . . .	320
11.3.5	Isolated IgG Subclass Deficiency . . . . .	321
11.3.6	Specific Antibody Deficiency with Normal Immunoglobulin Concentrations . . . . .	321
11.3.7	Transient Hypogammaglobulinemia of Infancy . . . . .	321
11.4	Therapy for Phagocytes Defects . . . . .	321
11.4.1	Severe Congenital Neutropenias/Cyclic Neutropenia . . . . .	321
11.4.2	Leukocyte Adhesion Deficiency . . . . .	323
11.4.3	Chronic Granulomatous Disease . . . . .	323
11.5	Therapy for Genetic Disorders of Immune Regulation . . . . .	323
11.5.1	Chediak-Higashi Syndrome . . . . .	323
11.5.2	Griscelli Syndrome, Type II . . . . .	324
11.5.3	X-Linked Lymphoproliferative Syndrome . . . . .	324
11.6	Therapy for Defects in Innate Immunity: Receptors and Signaling Components . . . . .	325
11.6.1	IRAK-4 Deficiency . . . . .	325
11.6.2	Mendelian Susceptibility to Mycobacterial Diseases . . . . .	325
11.6.3	Warts, Hypogammaglobulinemia, Infections, Myelokathexis (WHIM) Syndrome . . . . .	325
11.7	Therapy for Autoinflammatory Disorders . . . . .	325
11.7.1	Familial Mediterranean Fever . . . . .	325
11.7.2	Other Autoinflammatory Disorders . . . . .	326
11.8	Therapy for Complement Deficiencies . . . . .	326
11.8.1	Deficiencies of Classical, Lectin and Alternative Pathways Components . . . . .	326
11.8.2	Deficiencies of Terminal Pathway Components . . . . .	326
11.8.3	C1 Inhibitor Deficiency . . . . .	326
11.9	Therapy for Other Well-Defined Immunodeficiencies . . . . .	326
11.9.1	Ataxia-Telangiectasia . . . . .	326
11.9.2	Di George Syndrome . . . . .	327
11.9.3	Wiskott-Aldrich Syndrome . . . . .	328
11.9.4	Hyper-IgE Syndrome . . . . .	328
11.9.5	Chronic Mucocutaneous Candidiasis . . . . .	328
	<b>Index . . . . .</b>	<b>335</b>